ABEONA THERAPEUTICS INC.ABEO
Market cap
$248.11M
P/E ratio
| Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Cash and cash equivalents | 2 | 396,000 | 424,000 | 12 | 40 | 69 | 138 | 19 | 129 | 13 | 33 | 14 | 14 | 23 |
| Short-term investments | - | - | - | - | - | - | - | 66 | - | 82 | 12 | 38 | 38 | 74 |
| Restricted cash | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Other receivables | - | - | - | - | - | - | - | - | - | - | - | 0 | 2 | 2 |
| Prepaid expenses and other current assets | 39,000 | 251,000 | 77,000 | - | 315,000 | 155,000 | 3 | 4 | 3 | 3 | 7 | 0 | 1 | 1 |
| Total current assets | 3 | 2 | 575,000 | 12 | 41 | 69 | 141 | 89 | 132 | 98 | 55 | 53 | 56 | 101 |
| Property and equipment, net | 51,000 | 7,000 | 6,000 | 4,000 | 350,000 | 721,000 | 1 | 9 | 13 | 11 | 12 | 6 | 4 | 4 |
| Operating lease right-of-use assets | - | - | - | - | - | - | - | - | 8 | 7 | 9 | 5 | 4 | 4 |
| Other assets | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 |
| Total assets | 4 | 2 | 613,000 | 17 | 80 | 111 | 179 | 174 | 223 | 151 | 80 | 64 | 64 | 109 |
| Accounts payable | 2 | 2 | 863,000 | 2 | 875,000 | 4 | 2 | 6 | 4 | 5 | 4 | 2 | 2 | 3 |
| Accrued expenses | 857,000 | 857,000 | 857,000 | - | - | - | - | 4 | 6 | 3 | 6 | 4 | 6 | 6 |
| Current portion of long-term debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 6 |
| Current portion of operating lease liability | - | - | - | - | - | - | - | - | 2 | 2 | 2 | 2 | 1 | 1 |
| Current portion payable to licensor | - | - | - | - | - | - | - | - | - | - | - | - | 5 | - |
| Other current liabilities | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Total current liabilities | 12 | 7 | 9 | 3 | 1 | 8 | 6 | 20 | 39 | 42 | 17 | 8 | 13 | 17 |
| Long-term operating lease liabilities | - | - | - | - | - | - | - | - | 6 | 5 | 8 | 6 | 4 | 3 |
| Long-term debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 13 |
| Warrant liabilities | - | - | - | - | - | - | - | - | - | - | - | 20 | 31 | 32 |
| Total liabilities | 21 | 19 | 15 | 12 | 12 | 12 | 9 | 40 | 45 | 49 | 28 | 37 | 49 | 65 |
| Preferred stock - $0.01 par value; authorized 2,000,000 shares; No shares issued and outstanding as of December 31, 2024 and 2023, respectively | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Common stock - $0.01 par value; authorized 200,000,000 shares; 45,644,091 and 26,523,878 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 239,000 | 247,000 | 257,000 | 200,000 | 328,000 | 403,000 | 469,000 | 479,000 | 836,000 | 961,000 | 1 | 0 | 0 | 0 |
| Additional paid-in capital | 238 | 251 | 251 | 301 | 378 | - | - | - | - | - | - | 722 | 764 | 857 |
| Accumulated deficit | -255,441,000 | -267,972,000 | -266,421,000 | -296,074,000 | -310,600,000 | -332,473,000 | -359,792,000 | -410,188,000 | -486,470,000 | -570,704,000 | -655,640,000 | -695 | -749 | -813 |
| Accumulated other comprehensive loss | - | - | - | - | - | - | - | - | - | -10,000 | -27,000 | -0 | -0 | 0 |
| Total stockholders’ equity | -17,606,000 | -17,076,000 | -14,779,000 | 5 | 68 | 99 | 170 | 134 | 178 | 103 | 51 | 27 | 15 | 44 |
| Total liabilities and stockholders’ equity | 4 | 2 | 613,000 | 17 | 80 | 111 | 179 | 174 | 223 | 151 | 80 | 64 | 64 | 109 |